A detailed history of Lynx Investment Advisory transactions in Abb Vie Inc. stock. As of the latest transaction made, Lynx Investment Advisory holds 1,711 shares of ABBV stock, worth $341,344. This represents 0.24% of its overall portfolio holdings.

Number of Shares
1,711
Previous 1,610 6.27%
Holding current value
$341,344
Previous $276 Million 22.4%
% of portfolio
0.24%
Previous 0.2%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$163.84 - $199.33 $16,547 - $20,132
101 Added 6.27%
1,711 $338 Million
Q2 2024

Jul 09, 2024

BUY
$154.79 - $180.76 $249,211 - $291,023
1,610 New
1,610 $276 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $353B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Lynx Investment Advisory Portfolio

Follow Lynx Investment Advisory and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynx Investment Advisory, based on Form 13F filings with the SEC.

News

Stay updated on Lynx Investment Advisory with notifications on news.